About: Activity of fulvestrant in HER2-overexpressing advanced breast cancer     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Background: Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with HER2-positive disease are less responsive to endocrine therapies. Trastuzumab monotherapy results in objective responses in only similar to 15% of patients. Fulvestrant retains activity in cells overexpressing HER2 that are resistant to other endocrine treatments. This retrospective study evaluated response to fulvestrant treatment among HER2-positive patients with advanced breast cancer (ABC).
  • Background: Human epidermal growth factor receptor 2 (HER2) overexpression increases the aggressiveness of breast cancer cells resulting in poorer prognosis. Patients with HER2-positive disease are less responsive to endocrine therapies. Trastuzumab monotherapy results in objective responses in only similar to 15% of patients. Fulvestrant retains activity in cells overexpressing HER2 that are resistant to other endocrine treatments. This retrospective study evaluated response to fulvestrant treatment among HER2-positive patients with advanced breast cancer (ABC). (en)
Title
  • Activity of fulvestrant in HER2-overexpressing advanced breast cancer
  • Activity of fulvestrant in HER2-overexpressing advanced breast cancer (en)
skos:prefLabel
  • Activity of fulvestrant in HER2-overexpressing advanced breast cancer
  • Activity of fulvestrant in HER2-overexpressing advanced breast cancer (en)
skos:notation
  • RIV/00064165:_____/10:4243!RIV11-MZ0-00064165
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • V
http://linked.open...iv/cisloPeriodika
  • 6
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 245313
http://linked.open...ai/riv/idVysledku
  • RIV/00064165:_____/10:4243
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Advanced breast cancer; Faslodex; fulvestrant; HER2; human epidermal growth factor 2 (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • NL - Nizozemsko
http://linked.open...ontrolniKodProRIV
  • [27C7086160E9]
http://linked.open...i/riv/nazevZdroje
  • Annals of Oncology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 21
http://linked.open...iv/tvurceVysledku
  • Petruželka, Luboš
  • Robertson, J.F.R.
  • Steger, G. G.
  • Barni, S.
  • Gieseking, F.
  • Kaufman, B.
  • Neven, P.
  • Nole, F.
  • O\\\'Malley, F. P.
  • Pritchard, K. I.
  • Simon, S. D.
http://linked.open...ain/vavai/riv/wos
  • 000278223700019
issn
  • 0923-7534
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 67 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software